Sarah Pirio Richardson

Dr. Sarah Pirio Richardson


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2017 in Neurology
Verified
Journal Article
Closed access
PDF file
SRSarah Pirio Richardson
Sarah Pirio Richardson
AWAshley R. Wegele
Ashley R. Wegele
BSBetty Skipper
Betty Skipper
ADAmanda Deligtisch
Amanda Deligtisch
HJH.A. Jinnah
H.A. Jinnah
Objective: To determine the frequency of medication use in patients with dystonia enrolled in an international biorepository study. Methods: In a cross-sectional analysis, we included 2,026 participants enrolled at 37 sites in the United States, Canada, Europe, and Australia through Project 1 of the Dystonia Coalition, an international biorepository study. The primary aim was to assess the frequency of medication classes recommended for treating patients with dystonia, and the secondary aim was to compare characteristics (disease type, age, sex, duration of disease, comorbid conditions, severity). Results: Querying the database for the presence of any medication for dystonia used (includes both injectable and oral therapy), we found 73% using medications (n = 1,488) and 27% using no dystonia medications (n = 538). Furthermore, 61% of the total sample used botulinum toxin (BoNT) therapy alone or in combination. Differences were found in medication use patterns by dystonia type, with the lowest oral medication use in focal dystonia and highest use in generalized dystonia; by region, with highest BoNT therapy rate reported in Italy and the lowest in the Northeast region of the United States; and by focal dystonia subtype, with highest BoNT therapy alone in blepharospasm and spasmodic dysphonia (49%) and lowest in other cranial dystonia (32%). Conclusions: The majority of patients with dystonia enrolled in the Dystonia Coalition Project 1 were using medications to treat their dystonia. Overall, a complex picture of medication use patterns emerged, with factors such as region, disease duration, type of dystonia, disease severity, and psychiatric comorbidities all playing a significant role.

3 May 2017 in Frontiers in Neurology
Verified
Journal Article
Open access
SRSarah Pirio Richardson
Sarah Pirio Richardson
EAEckart Altenmüller
Eckart Altenmüller
KAKatharine Alter
Katharine Alter
RARon L. Alterman
Ron L. Alterman
RCRobert Chen
Robert Chen
MHMark Hallett
Mark Hallett
Dystonia, which causes intermittent or sustained abnormal postures and movements, can present in a focal or a generalized manner. In the limbs, focal dystonia can occur in either the upper or lower limbs and may be task-specific causing abnormal motor performance for only a specific task, such as in writer’s cramp, runner’s dystonia or musician’s dystonia. Focal limb dystonia can be non-task-specific and may, in some circumstances, be associated with parkinsonian disorders. The true prevalence of focal limb dystonia is not known and is likely currently under-estimated, leaving a knowledge gap and an opportunity for future research. The pathophysiology of focal limb dystonia shares some commonalities with other dystonias with a loss of inhibition in the central nervous system and a loss of the normal regulation of plasticity, called homeostatic plasticity. Functional imaging studies revealed abnormalities in several anatomical networks that involve the cortex, basal ganglia and cerebellum. Further studies should focus on distinguishing cause from effect in both physiology and imaging studies to permit focus on most relevant biological correlates of dystonia. There is no specific therapy for the treatment of limb dystonia given the variability in presentation, but off-label botulinum toxin therapy is often applied to focal limb and task-specific dystonia. Various rehabilitation techniques have been applied and rehabilitation interventions may improve outcomes, but small sample size and lack of direct comparisons between methods to evaluate comparative efficacy limits conclusions. Finally, noninvasive and invasive therapeutic modalities have been explored in small studies with design limitations that do not yet clearly provide direction for larger clinical trials that could support new clinical therapies. Given these gaps in our clinical, pathophysiologic and therapeutic knowledge, we have identified priorities for future research including: the development of diagnostic criteria for limb dystonia, more precise phenotypic characterization and innovative clinical trial design that considers clinical heterogeneity and limited available number of participants.

29 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SRSarah Pirio Richardson
Sarah Pirio Richardson
STSule Tinaz
Sule Tinaz
RCRobert Chen
Robert Chen
Dystonia is characterized by abnormal posturing due to sustained muscle contraction, which leads to pain and significant disability. New therapeutic targets are needed in this disorder. The objective of this randomized, sham-controlled, blinded exploratory study is to identify a specific motor system target for non-invasive neuromodulation and to evaluate this target in terms of safety and tolerability in the cervical dystonia (CD) population. Eight CD subjects were given 15-minute sessions of low-frequency (0.2 Hz) repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex (MC), dorsal premotor cortex (dPM), supplementary motor area (SMA), anterior cingulate cortex (ACC) and a sham condition with each session separated by at least two days. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) score was rated in a blinded fashion immediately pre- and post-intervention. Secondary outcomes included physiology and tolerability ratings. The mean change in TWSTRS severity score by site was 0.25 ± 1.7 (ACC), -2.9 ± 3.4 (dPM), -3.0 ± 4.8 (MC), -0.5 ± 1.1 (SHAM), and -1.5 ± 3.2 (SMA) with negative numbers indicating improvement in symptom control. TWSTRS scores decreased from Session 1 (15.1 ± 5.1) to Session 5 (11.0 ± 7.6). The treatment was tolerable and safe. Physiology data were acquired on 6 of 8 subjects and showed no change over time. These results suggest rTMS can modulate CD symptoms. Both dPM and MC are areas to be targeted in further rTMS studies. The improvement in TWSTRS scores over time with multiple rTMS sessions deserves further evaluation. ClinicalTrials.gov NCT01859247

21 October 2008 in Experimental Brain Research
Verified
Journal Article
Closed access
PDF file
SRSarah Pirio Richardson
Sarah Pirio Richardson
BBBarbara Bliem
Barbara Bliem
BVBernhard Voller
Bernhard Voller
NDNguyet Dang
Nguyet Dang
MHMark Hallett
Mark Hallett

7 April 2014 in Movement Disorders
Verified
Journal Article
Closed access
SRSarah Pirio Richardson
Sarah Pirio Richardson
SBSandra Beck
Sandra Beck
BBBarbara Bliem
Barbara Bliem
MHMark Hallett
Mark Hallett

1 July 2015 in Clinical Neurophysiology
Verified
Journal Article
Closed access
SRSarah Pirio Richardson
Sarah Pirio Richardson